Overall, both machine learning techniques had an equivalent performance. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Research
27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
These findings highlight hippocampal atrophy as a key pathway linking Aβ burden to cognitive impairment. 4 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The MMSE model achieves a mean absolute error (MAE) of 1.84 (95% CI: 1.64-2.04) internally and 2.19 in external validation. 5 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
39/100
The sample included 61 participants (55.7% female), aged 18-58, with a median education of 12 years (IQR: 10-14). 5 key findings →
Participants: 61 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Integrating EEG features with plasma biomarkers improves prediction of cognitive function from mild cognitive impairment to moderate dementia, pending external validation. 1 key finding →
Participants: 75 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Neurodegenerative brain changes can affect the functional connectivity strength between nodes of the default-mode network (DMN), which may underlie changes in cognitive performance. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Mild cognitive impairment is defined as greater cognitive decline than expected for a person at a particular age and is sometimes considered a stage between healthy aging and Alzheimer's disease or other dementia syndromes. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
A linear mixed effects model revealed a significant interaction in the right parietal lobe: the MCI group showed increased connectivity while the healthy elders showed decreased connectivity. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Locus of control (LOC) is an important personality trait. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The main advantages of optical retinal imaging may allow researchers to achieve deeper analysis of retinal ganglion cells (GC) in vivo using optical coherence tomography (OCT). 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
In recent years, electroencephalography (EEG) has emerged as a low-cost, accessible and objective tools for the early diagnosis of Alzheimer's disease (AD). 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Insomnia is a common problem in older people, especially in patients with mild cognitive impairment (MCI) whose circadian rhythm is often compromised. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Loneliness is a perception of social and emotional isolation that increases in prevalence among older adults during the eighth decade of life. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Sporadic late-onset Alzheimer disease (LOAD) preceded by mild cognitive impairment (MCI) is the most common type of dementia. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
EEG characteristics that correlate with the cognitive functions are important in detecting mild cognitive impairment (MCI) in T2DM. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Both (18)F-FDG and (11)C-PiB imaging appear to be of limited use for predicting the progression from MCI to dementia due to AD in short-term follow-up, irrespective of the strategy of analysis. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The objective of this study was to evaluate the effect of apolipoprotein E (APOE) epsilon 4 allele on regional cerebral perfusion (rCBF) changes using arterial spin labeling (ASL) magnetic resonance imaging (MRI) in subjects who are carriers or noncarriers of this risk factor for Alzheimer disease (AD). 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
In the literature it is commonly reported that several spatial abilities decline with normal aging, even though such a decline is not uniform. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Future research should address the question of whether performance-based functional measures, as well as simple queries regarding whether functional activities take longer than usual to complete, may improve the prediction of future cognitive decline and disease progression among those individuals in whom MCI represents impending dementia. 1 key finding →
Design: cross-sectional Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
In this study 5 patients with mild cognitive impairment (MCI) and 9 Alzheimer's disease (AD) patients underwent respectively 3- and 5-year follow-up positron emission tomography (PET) studies with N-methyl [(11)C] 2-(4-methylaminophenyl)-6-hydroxy-benzothiazole ((11)C-PIB) and (18)F-fluorodeoxyglucose ((18)F-FDG) to understand the time courses in AD disease processes. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Deep-learning methods (especially convolutional neural networks) using structural magnetic resonance imaging (sMRI) data have been successfully applied to computer-aided diagnosis (CAD) of Alzheimer's disease (AD) and its prodromal stage [i.e., mild cognitive impairment (MCI)]. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Patients (N = 2,512) receiving lecanemab infusion had a mean age of 75.4 (standard deviation = 5.7) years as compared to 80.8 (8.9) years in patients with MCI/AD not receiving the infusion. 5 key findings →
Participants: 2,512 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
These preliminary findings reveal white matter alterations associated with consensus MCI diagnosis and to socioeconomic differences in a clinical cohort of rural‐dwelling older adults. 5 key findings →
Participants: 69 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The fMRI entropy classifier matched the tau PET model in accuracy and outperformed it in F1 score (0.64 vs. 0.61) and area under the curve (AUC; 0.73 vs. 0.67). 4 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Early diagnosis of mild cognitive impairment (MCI) and Alzheimer's disease (AD) with mild dementia is becoming increasingly important to enable patients to receive appropriate treatment with available amyloid-targeting therapies. 5 key findings →
Design: narrative review Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
From across this tag
10 of the 2,090 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
- A new systematic method of measurement and diagnosis of "mild cognitive impairment" and dementia according to ICD-10 and DSM-III-R criteria
- Tau Positron Emission Tomography for Predicting Dementia in Individuals With Mild Cognitive Impairment
- Hippocampal activation in adults with mild cognitive impairment predicts subsequent cognitive decline
- Pathologic Correlates of Nondemented Aging, Mild Cognitive Impairment, and Early-Stage Alzheimer's Disease
- Association of mediterranean diet with mild cognitive impairment and Alzheimer's disease: a systematic review and meta-analysis
- Cognitive Performance and Cerebrospinal Fluid Markers in Preclinical Alzheimer's Disease: Results from the Gothenburg H70 Birth Cohort Studies
- Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist--a review of preclinical data
- Validity of a novel computerized cognitive battery for mild cognitive impairment
- Low-dose ladostigil for mild cognitive impairment: A phase 2 placebo-controlled clinical trial
- A phase-II randomized controlled pilot study of nicotinamide riboside supplementation in older adults with amnestic mild cognitive impairment
Where “Free full text” comes from
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
How the 0–100 score works — and why some entries are capped
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
- Journal tier up to 10 pts
- Journal's citation record up to 4 pts
- Study design up to 12 pts
- Strength of evidence up to 5 pts
- Peer-review validation up to 10 pts
- How recent up to 5 pts
- Sample size up to 4 pts
- Effect reported up to 3 pts
- Studied in people up to 3 pts
- Randomised / blinded up to 2 pts
- Times cited up to 7 pts
- Citations per year up to 5 pts
- Impact for its field and year up to 6 pts
- Cited by studies here up to 6 pts
- Still being cited up to 4 pts
- Senior author's track record up to 4 pts
- Institution's track record up to 3 pts
- Multi-centre collaboration up to 3 pts
- Indexed in PubMed up to 2 pts
- Free to read up to 2 pts
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
What this library is — and isn't
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →